1. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

   • Jill R. Dietz
   • Meena S. Moran
   • Katharine A. Yao

   Editorial Open access 24 April 2020 Pages: 487 - 497

2. Healthcare providers’ adherence to breast cancer guidelines in Europe: a systematic literature review

   • Ena Niño de Guzmán
   • Yang Song
   • Ignacio Ricci-Cabello

   Review Open access 06 May 2020 Pages: 499 - 518

   

3. HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas

   • Tiansheng Shen
   • Hiroaki Nitta
   • Zaibo Li

   Preclinical study 25 April 2020 Pages: 519 - 527

   

4. MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients

   • Brian G. Hunt
   • Christina A. Wicker
   • Susan E. Waltz

   Preclinical study 27 April 2020 Pages: 529 - 540

   

5. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer

   • Abrar I. Aljohani
   • Chitra Joseph
   • Emad A. Rakha

   Preclinical Study Open access 29 April 2020 Pages: 541 - 551

   

6. PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies

   • E. S. Stovgaard
   • M. Bokharaey
   • E. Balslev

   Preclinical study 02 May 2020 Pages: 553 - 560

   

7. Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study

   • Ruo-Xi Wang
   • Peng Ji
   • Sheng Chen

   Preclinical study 02 May 2020 Pages: 561 - 570

   

8. Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy

   • Sharon A. O’Toole
   • Cathy Spillane
   • John J. O’Leary

   Preclinical study Open access 06 May 2020 Pages: 571 - 580

   

9. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers

   • Inge-Marie Obdeijn
   • Ritse M. Mann
   • Maartje J. Hooning

   Clinical trial Open access 24 April 2020 Pages: 581 - 588

   

10. Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts

    • Mengmeng Jia
    • Xi Lin
    • Rengaswamy Sankaranarayanan

    Clinical trial 27 April 2020 Pages: 589 - 597

    

11. Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation

    • Ennie Bijkerk
    • Sander M. J. van Kuijk
    • Stefania M. H. Tuinder

    Clinical trial Open access 28 April 2020 Pages: 599 - 610

    

12. A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction

    • Utku Dolen
    • Melissa Thornton
    • Terence M. Myckatyn

    Clinical trial 30 April 2020 Pages: 611 - 621

    

13. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

    • Peter H. O’Donnell
    • Vassily Trubetskoy
    • the Translational Breast Cancer Research Consortium (TBCRC)

    Clinical trial 06 May 2020 Pages: 623 - 633

    

14. Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography

    • Asha Heydon-White
    • Hiroo Suami
    • Karen C. Peebles

    Clinical trial 06 May 2020 Pages: 635 - 644

    

15. Chemotherapy use near the end-of-life in patients with metastatic breast cancer

    • Luisa Edman Kessler
    • Johnny Sigfridsson
    • Alexios Matikas

    Clinical trial Open access 07 May 2020 Pages: 645 - 651

16. Medical costs associated with metastatic breast cancer in younger, midlife, and older women

    • Justin G. Trogdon
    • Christopher D. Baggett
    • Stephanie B. Wheeler

    Epidemiology 28 April 2020 Pages: 653 - 665

    

17. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study

    • Inés Gómez-Acebo
    • Trinidad Dierssen-Sotos
    • Javier Llorca

    Epidemiology Open access 30 April 2020 Pages: 667 - 678

    

18. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

    • Chun Wang
    • Zhaomei Mu
    • Hushan Yang

    Epidemiology 04 May 2020 Pages: 679 - 689

    

19. Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?

    • Kadri Altundag

    Letter to the Editor 27 April 2020 Pages: 691 - 691

20. Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life

    • Leonardo Ribeiro Soares
    • Victor Domingos Lisita Rosa
    • Ruffo Freitas-Junior

    Letter to the Editor 29 April 2020 Pages: 693 - 694